Janux Therapeutics, Inc. quarterly report, Q2 FY2023

Janux Therapeutics, Inc. — Q2 2023 Form 10-Q

Reporting period: Quarter and six months ended June 30, 2023. Janux is a clinical-stage biopharmaceutical company developing tumor-activated cancer immunotherapies through its TRACTr and TRACIr platforms. It has no product sales; reported revenue is from its Merck collaboration.

Financial performance and liquidity

MetricQ2 2023Q2 2022Six months 2023Six months 2022
Collaboration revenue$1.1 million$2.4 million$3.1 million$4.0 million
Research and development expense$14.9 million$14.1 million$30.8 million$24.3 million
General and administrative expense$6.9 million$5.5 million$13.3 million$10.5 million
Net loss$17.5 million$16.9 million$35.0 million$30.3 million
Net loss per share, basic and diluted$0.42$0.41$0.84$0.73
  • Six-month operating cash outflow was $29.0 million, versus $17.6 million in 2022. Investing activities provided $9.1 million, mainly from net investment maturities; financing provided $2.1 million.
  • At June 30, cash and cash equivalents were $33.7 million and short-term investments were $269.6 million; restricted cash was $0.8 million. Cash, cash equivalents and short-term investments totaled approximately $303.3 million, excluding restricted cash.
  • Current assets were $309.3 million and current liabilities $17.9 million. The company reported no borrowings; operating lease liabilities totaled $25.2 million, including $1.4 million current. Accumulated deficit was $145.4 million.
  • Margins are not meaningful for this pre-commercial company; it has not generated product revenue.

Changes versus prior comparable periods

  • For the first half, revenue declined $0.8 million as Merck research-service hours decreased. Operating expenses rose $9.4 million, including R&D up $6.5 million and G&A up $2.9 million; the net loss widened $4.7 million.
  • Higher interest rates drove interest income to $6.1 million for the first half, versus $0.5 million in 2022, partially offsetting higher operating losses.
  • R&D spending shifted among programs: first-half JANX007 direct costs rose $1.4 million and JANX008 costs declined $2.2 million; preclinical and unallocated direct costs and indirect costs increased.
  • Available-for-sale investments had $1.1 million of gross unrealized losses at June 30, which management attributed primarily to interest-rate and market conditions, not credit factors. No credit-loss allowance was recorded.

Outlook, commentary and risks

  • Management said existing cash and cash equivalents and short-term investments should fund anticipated needs for at least 12 months following the filing. The company expects substantial losses and increased R&D and G&A expenses and says additional financing will be needed to develop candidates through approval and commercialization.
  • In July 2023, after quarter-end, Janux completed an underwritten offering of common stock and pre-funded warrants for $59.0 million gross proceeds and estimated $56.5 million net proceeds. Management said the additional capital positions it to advance another program into clinical trials; it was assessing preclinical pipeline priorities.
  • JANX007 was in a Phase 1 trial for metastatic castration-resistant prostate cancer. Janux reported July interim data with PSA reductions and described a potentially differentiated profile in CRS, healthy-tissue toxicity and pharmacokinetics; these were preliminary company-reported findings, not confirmatory outcomes.
  • JANX008 was in Phase 1 development for several solid tumors; its first patient was dosed in April 2023. The company expected to select a TROP2-TRACTr development candidate and be ready to submit an IND for JANX009 in 2023.
  • Merck has selected two collaboration targets. Remaining performance obligations primarily concern research and joint-committee work for the second target, with an estimated 1.2 years of research services remaining at June 30. Merck may terminate the agreement unilaterally; milestones and royalties are contingent.
  • Key risks include early-stage clinical uncertainty, safety risks including cytokine release syndrome and healthy-tissue toxicity, reliance on third-party clinical and manufacturing providers, need for future capital and potential dilution, dependence on Merck collaboration revenue, and macroeconomic, banking, inflation and interest-rate conditions. The company reported no material legal proceedings and said disclosure controls were effective.

Important facts for investors to verify

  • Review the full JANX007 interim clinical dataset, including patient numbers, dose levels, duration of follow-up, safety events and durability of PSA responses.
  • Track JANX008 trial progress and the timing and evidence supporting the expected TROP2 candidate selection and JANX009 IND submission.
  • Reassess cash runway using actual clinical-trial spending, the July offering’s final net proceeds and any future financing or ATM issuance.
  • Monitor Merck research activity, remaining performance obligations, target progress and any milestone, termination or royalty developments.
  • Assess investment portfolio liquidity and interest-rate exposure, as well as the dilution impact of outstanding options, reserved shares and future equity issuance.